Core Insights - Ventas, Inc. (VTR) is a healthcare REIT with a market cap of $36.1 billion, focusing on senior housing, medical office buildings, life science facilities, and healthcare-related properties [1] - The company is expected to announce its fiscal Q4 earnings for 2025 soon, with analysts predicting a profit of $0.89 per share, a 9.9% increase from the previous year [2] - Ventas has consistently exceeded Wall Street's bottom-line estimates for the last four quarters, with a forecasted FFO of $3.48 per share for the current fiscal year, representing a 9.1% increase from fiscal 2024 [3] Financial Performance - In Q3, Ventas reported total revenue of $1.5 billion, a 20.4% year-over-year increase, surpassing consensus estimates by 4.2% [5] - The company's normalized FFO for Q3 was $0.88, which improved 10% from the same quarter last year, exceeding analyst expectations [5] - The strong performance was attributed to the senior housing operating portfolio (SHOP), which saw double-digit organic growth year-over-year [5] Market Performance - Over the past 52 weeks, Ventas shares have increased by 32.6%, outperforming the S&P 500 Index's 19.3% return and the State Street Real Estate Select Sector SPDR ETF's 2.3% increase [4] - Wall Street analysts have a highly optimistic outlook for VTR, with a "Strong Buy" rating from 16 out of 21 analysts, and a mean price target of $86.40, indicating a 12.3% potential upside [6]

Core Insights - Healthpeak Properties, Inc. (DOC) is a publicly traded real estate investment trust (REIT) with a market cap of $11.6 billion, focusing on a diversified portfolio of healthcare properties [1][2] Company Overview - DOC is classified as a large-cap stock, emphasizing its significant size and influence in the healthcare REIT sector [2] - The company specializes in high-quality healthcare assets that benefit from long-term leases and stable cash flows [2] Stock Performance - DOC's stock has decreased by 21.9% from its 52-week high of $21.28, reached on March 10, and has underperformed the Dow Jones Industrial Average (DOWI) [3][4] - Over the past three months, DOC shares have declined by 8.1%, while DOWI has risen by 5.7% [3] - In the last 52 weeks, DOC has fallen by 20.6%, compared to DOWI's increase of 10.4% [4] - The stock has been trading below its 200-day moving average since late October and has recently dipped below its 50-day moving average [4] Financial Performance - In the third quarter, Healthpeak reported total revenue of approximately $705.9 million, slightly exceeding expectations, supported by stable outpatient medical and lab leasing activity [5] - The company generated Nareit FFO of about $0.45 per share and Adjusted FFO of $0.46, aligning with guidance [5] - Healthpeak recorded a net loss of roughly $0.17 per share, primarily due to equity losses from unconsolidated ventures, which affected diluted EPS [5] - Occupancy trends were mixed, with rising outpatient medical demand but pressure on lab occupancy [5] Competitive Position - Healthpeak's underperformance is notable when compared to its competitor, Omega Healthcare Investors, Inc. (OHI), which has seen a 13.3% rise over the past 52 weeks and an 18.8% increase over the past six months [6]

Core Viewpoint - Ventas, Inc. is a leading U.S. real estate investment trust (REIT) focused on healthcare and senior living assets, with a market cap of $37.6 billion, and is well-positioned to benefit from the aging population trend [1][2]. Company Overview - Ventas operates a diversified portfolio that includes senior housing communities, medical office buildings, life science facilities, and hospitals, targeting the growing aging population [1]. - The company is classified as a large-cap stock, valued over $10 billion, and is perceived as having stable cash flows and moderate growth prospects [2]. Stock Performance - Ventas shares have decreased by 5.1% from their 52-week high of $81.89, but have increased by 12.3% over the past three months, outperforming the S&P 500 Index's 5.4% gain during the same period [3]. - Year-to-date, Ventas shares have risen by 32%, surpassing the S&P 500's 17.1% increase, and have gained nearly 27.1% over the past 52 weeks compared to the S&P 500's 14.1% rise [4]. Financial Performance - In Q3, Ventas reported a 20.4% increase in total revenues to $1.5 billion, exceeding consensus estimates by 3.9%, driven by an 8% year-over-year rise in same-store cash operating revenues [5]. - The company has actively expanded its portfolio, deploying $2.2 billion towards senior housing acquisitions in the first nine months of 2025 [5]. Competitive Landscape - Ventas's competitor, Welltower Inc. (WELL), has shown stronger stock performance, with a year-to-date increase of 51.6% and a 52-week rise of 47.8% [6].